Goelzer Investment Management Inc. acquired a new position in shares of Gilead Sciences, Inc. (NASDAQ:GILD) in the first quarter, according to its most recent filing with the Securities & Exchange Commission. The firm acquired 2,895 shares of the biopharmaceutical company’s stock, valued at approximately $216,000.

Several other large investors have also recently bought and sold shares of GILD. OLD National Bancorp IN grew its holdings in shares of Gilead Sciences by 3.4% during the fourth quarter. OLD National Bancorp IN now owns 20,166 shares of the biopharmaceutical company’s stock worth $1,310,000 after buying an additional 666 shares in the last quarter. Hamlin Capital Management LLC grew its stake in Gilead Sciences by 0.8% in the fourth quarter. Hamlin Capital Management LLC now owns 752,742 shares of the biopharmaceutical company’s stock valued at $48,913,000 after purchasing an additional 5,822 shares in the last quarter. Ackerman Capital Advisors LLC grew its stake in Gilead Sciences by 71.4% in the fourth quarter. Ackerman Capital Advisors LLC now owns 6,000 shares of the biopharmaceutical company’s stock valued at $390,000 after purchasing an additional 2,500 shares in the last quarter. Hamilton Wealth LLC bought a new position in Gilead Sciences in the fourth quarter valued at approximately $1,747,000. Finally, Bristlecone Advisors LLC grew its stake in Gilead Sciences by 3.8% in the fourth quarter. Bristlecone Advisors LLC now owns 8,320 shares of the biopharmaceutical company’s stock valued at $541,000 after purchasing an additional 305 shares in the last quarter. Institutional investors and hedge funds own 80.66% of the company’s stock.

A number of research firms have weighed in on GILD. Robert W. Baird restated a “hold” rating and issued a $76.00 price target on shares of Gilead Sciences in a research note on Wednesday, April 29th. SunTrust Banks downgraded Gilead Sciences from a “hold” rating to a “sell” rating and set a $70.00 price target for the company. in a research note on Friday, May 1st. Oppenheimer lifted their target price on Gilead Sciences from $80.00 to $90.00 and gave the stock an “outperform” rating in a research note on Friday, May 1st. Needham & Company LLC reiterated a “hold” rating on shares of Gilead Sciences in a research note on Sunday, April 19th. Finally, SVB Leerink lifted their target price on Gilead Sciences from $68.00 to $85.00 and gave the stock a “market perform” rating in a research note on Friday, May 1st. Six equities research analysts have rated the stock with a sell rating, sixteen have given a hold rating and ten have issued a buy rating to the company. Gilead Sciences presently has an average rating of “Hold” and an average target price of $78.19.

GILD stock opened at $76.26 on Friday. The stock’s 50 day simple moving average is $77.60 and its 200 day simple moving average is $69.76. Gilead Sciences, Inc. has a fifty-two week low of $60.89 and a fifty-two week high of $85.97. The company has a debt-to-equity ratio of 1.00, a quick ratio of 2.92 and a current ratio of 3.04. The company has a market cap of $95.87 billion, a P/E ratio of 19.60, a price-to-earnings-growth ratio of 3.31 and a beta of 0.72.

Gilead Sciences (NASDAQ:GILD) last posted its quarterly earnings results on Thursday, April 30th. The biopharmaceutical company reported $1.68 earnings per share for the quarter, topping analysts’ consensus estimates of $1.57 by $0.11. Gilead Sciences had a return on equity of 35.44% and a net margin of 21.84%. The business had revenue of $5.55 billion for the quarter, compared to the consensus estimate of $5.44 billion. During the same period in the prior year, the business earned $1.67 EPS. The firm’s revenue for the quarter was up 5.1% on a year-over-year basis. Equities analysts predict that Gilead Sciences, Inc. will post 6.34 earnings per share for the current year.

The business also recently disclosed a quarterly dividend, which will be paid on Monday, June 29th. Stockholders of record on Friday, June 12th will be paid a $0.68 dividend. This represents a $2.72 annualized dividend and a dividend yield of 3.57%. The ex-dividend date of this dividend is Thursday, June 11th. Gilead Sciences’s dividend payout ratio (DPR) is presently 44.30%.

In other news, Director John Francis Cogan sold 2,413 shares of the stock in a transaction that occurred on Monday, March 9th. The stock was sold at an average price of $77.97, for a total value of $188,141.61. Following the completion of the sale, the director now directly owns 57,273 shares of the company’s stock, valued at $4,465,575.81. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, EVP Brett A. Pletcher sold 10,441 shares of the stock in a transaction that occurred on Monday, March 2nd. The stock was sold at an average price of $70.88, for a total value of $740,058.08. Following the completion of the sale, the executive vice president now directly owns 25,085 shares of the company’s stock, valued at $1,778,024.80. The disclosure for this sale can be found here. Over the last three months, insiders sold 60,585 shares of company stock valued at $4,671,283. Company insiders own 0.13% of the company’s stock.

About Gilead Sciences

Gilead Sciences, Inc, a research-based biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical needs in the United States, Europe, and internationally. The company's products include Biktarvy, Descovy, Odefsey, Genvoya, Stribild, Complera/Eviplera, Atripla, and Truvada for the treatment of human immunodeficiency virus (HIV) infection in adults; and Vosevi, Vemlidy, Epclusa, Harvoni, and Viread products for treating liver diseases.

Further Reading: What are popular green investing opportunities?

Want to see what other hedge funds are holding GILD? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Gilead Sciences, Inc. (NASDAQ:GILD).

Institutional Ownership by Quarter for Gilead Sciences (NASDAQ:GILD)

Receive News & Ratings for Gilead Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gilead Sciences and related companies with MarketBeat.com's FREE daily email newsletter.